← Eichor
Study identifier: NCT07483723 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Glucose Profiles in Women With Polycystic Ovary Syndrome

Condition: Polycystic Ovary Syndrome · Glucose Profile · Insulin Resistance  ·  Sponsor: Centre Hospitalier Universitaire, Amiens

PhaseNA
Planned participants80
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

Polycystic ovary syndrome is a very common condition that is associated with metabolic complications. Patients with polycystic ovary syndrome exhibit insulin resistance and are at greater risk to develop type 2 diabetes. This syndrome is heterogeneous, classified according to 4 phenotypes (A-D). It seems that certain phenotypes are less exposed to insulin resistance and metabolic complications. However, only a few studies have evaluated the glucose profile according to phenotype. New technologies now make it possible to monitor glucose levels continuously. The aim of this project is to evaluate glucose profile parameters using continuous glucose monitoring, and to compare these profiles according to different PCOS phenotypes.

This description comes directly from the study's public registry record.

Talk to the study team

Abdallah Al-Salameh, Pr  ·  33+3.22.08.83.71  ·  Al-Salameh.Abdallah@chu-amiens.fr

Always discuss trial participation with your own doctor first.

Locations (1)

CHRU AmiensSalouël, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07483723